Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus

Maria Ristig, Henning Drechsler, Jeffrey Crippin, Mauricio Lisker-Melman, Pablo Tebas

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Chronic viral hepatitis has emerged as one of the leading causes of morbidity and mortality among HIV-positive patients. These individuals are at risk for aggressive chronic active hepatitis, cirrhosis, and hepatocellular carcinoma, and eventually, death. Currently available therapies for hepatitis B are limited and include interferon-α, lamivudine (3TC), and adefovir. Tenofovir (TDF), a recently approved drug for the treatment of HIV, is also active against hepatitis B. We report the case of a HIV-positive patient with liver cirrhosis secondary to chronic hepatitis B virus (HBV) with evidence of resistance to 3TC. The patient was initially accepted as a liver transplant candidate. However, when TDF was added to his treatment, a remarkable virologic and histopathologic improvement was achieved. The patient was subsequently removed from the liver transplant program and has not suffered from any further hepatic complications.

Original languageEnglish (US)
Pages (from-to)439-442
Number of pages4
JournalAIDS Patient Care and STDs
Issue number9
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus'. Together they form a unique fingerprint.

Cite this